Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...
Routine use of tolvaptan in clinical practice may slow eGFR decline for patients with autosomal dominant polycystic kidney ...
NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer ...
During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.
The estimated glomerular filtration rate (eGFR) is a blood test to assess kidney function. The formula for calculating eGFR takes the patient’s body size, age, and sex into account to predict ...
Long-term high-intensity interval training may reduce the risk for the decline of kidney function in older adults, a study ...
Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...
Weight fluctuation was associated with a greater risk for diabetic kidney disease progression among individuals with type 1 diabetes.
Research shows multiple factors drive CKD risk in lupus nephritis, including nephritic flares, baseline hypertension, renal ...
Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback